Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season - Takeaways - MDSpire

Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season

  • By

  • Eduardo Azziz-Baumgartner

  • Alicia Budd

  • Justin S. Lee

  • A. Danielle Iuliano

  • Sascha R. Ellington

  • Min Z. Levine

  • Xiao-yu Zheng

  • Larisa Gubareva

  • Katherine Adams

  • Jennifer DeCuir

  • Catherine H. Bozio

  • Carrie Reed

  • Marie K. Kirby

  • Benjamin Rambo-Martin

  • Jefferson M. Jones

  • Matthew Biggerstaff

  • Shikha Garg

  • Charles Todd Davis

  • Tom T. Shimabukuro

  • Erin Burns

  • Rebecca Kondor

  • Sonja J. Olsen

  • Vivien G. Dugan

  • VISION Coauthors

  • Stephanie A. Irving

  • Allison L. Naleway

  • Kristin Dascomb

  • Tamara Sheffield

  • Malini B. DeSilva

  • Sara Y. Tartof

  • Lina S. Sy

  • Nicola P. Klein

  • Ousseny Zerbo

  • Shaun J. Grannis

  • Brian E. Dixon

  • Melissa S. Stockwell

  • Ashley B. Stephens

  • Toan C. Ong

  • Michelle A. Barron

  • Sarah W. Ball

  • Zachary A. Weber

  • Emily L. Reeves

  • Caitlin S. Ray

  • June 17, 2026

  • 0 min

Share

  • 1

    The CDC identified 10 mutations in the hemagglutinin surface protein of influenza A(H3N2) viruses during surveillance in August 2025.

  • 2

    Antigenic characterization indicated these A(H3N2) viruses showed evidence of antigenic drift compared to the vaccine reference virus.

  • 3

    Influenza A(H3N2) subclade K viruses caused a severe influenza epidemic in Australia and became predominant in the Northern Hemisphere.

  • 4

    The CDC's influenza virus surveillance involves collaboration with about 300 clinical laboratories and 100 public health laboratories across the US.

  • 5

    FluSurv-NET conducts population-based surveillance of laboratory-confirmed influenza hospitalizations, covering approximately 10% of the US population.

Original Source(s)

Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season

  • by Eduardo Azziz-Baumgartner, Alicia Budd, Justin S. Lee, A. Danielle Iuliano, Sascha R. Ellington, Min Z. Levine, Xiao-yu Zheng, Larisa Gubareva, Katherine Adams, Jennifer DeCuir, Catherine H. Bozio, Carrie Reed, Marie K. Kirby, Benjamin Rambo-Martin, Jefferson M. Jones, Matthew Biggerstaff, Shikha Garg, Charles Todd Davis, Tom T. Shimabukuro, Erin Burns, Rebecca Kondor, Sonja J. Olsen, Vivien G. Dugan, VISION Coauthors, Stephanie A. Irving, Allison L. Naleway, Kristin Dascomb, Tamara Sheffield, Malini B. DeSilva, Sara Y. Tartof, Lina S. Sy, Nicola P. Klein, Ousseny Zerbo, Shaun J. Grannis, Brian E. Dixon, Melissa S. Stockwell, Ashley B. Stephens, Toan C. Ong, Michelle A. Barron, Sarah W. Ball, Zachary A. Weber, Emily L. Reeves, Caitlin S. Ray

  • June 17, 2026

Related Content

Mycobacterium abscessus infection in a young man with cystic fibrosis: a case report and literature review

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants